Adma Biologics Inc · NASDAQ:ADMA
Adma Biologics — Investor Presentation (May 2024)
29 slides from Adma Biologics's investor presentation, May 17, 2024
Slide 1: Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology
ADMA Biologics Realizing the Potential of Specialty Biologicswith Groundbreaking Immunotechnology May 2024 NASDAQ: ADMA
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements," pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Company”), including, without limitat
Slide 3: Who We Are: A Specialty Biologics Company
Who We Are: A Specialty Biologics Company ADMA Biologics ian end-to-end commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty biologics for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infec
Slide 4: ADMA Investment Highlights
DIFFERENTIATION VERTICAL INTEGRATION ASSET DURABILITY UPSIDE STRONG BALANCE SHEET Differentiated U.S. Specialty Biologics Opportunity in a Large and Growing End-Market Vertically Integrated Supply Chain with Innovative Technology and Production Processes Unique Scarcity Value and Asset Durability Po
Slide 5: Differentiated Opportunity in a Large & Growing Market
Differentiated Opportunity in a Large & Growing Market One of six manufacturers in a historically undersupplied U.S. IG market The only fully vertically integrated U.S.-domiciled fractionator Four major producers (Grifols, CSL Behring, Shire and Octapharma) collectively account for >94% of U.S. IG m
Slide 6: Vertically Integrated Supply Chain with Innovative Technology & Production Processes
In-House Fill-Finish Functions Vertically Integrated Supply Chain with Innovative Technology& Production Processes 10 FDA-licensed plasma collection facilities Contractually obligated third-party supply agreements expected to supplement the growing internal plasma collections Well-positioned infrast
Slide 7: Unique Scarcity Value and Asset Durability
Unique Scarcity Value and Asset Durability Capital requirements, regulatory approvals and manufacturing lead time prohibit manufacturers from quickly increasing output and filling demand in end-market supply Unique and complex manufacturing process with a long production cycle (7-12 months) Market d
Slide 8: Potential Upside Through Production Yield Enhancements and New Product Pipeline
Potential Upside Through Production Yield Enhancementsand New Product Pipeline Program Current plant infrastructure supports well-defined pathway to $410M+ revenues by 2025 Advancing initiative to capture additional IG production yields from same quantities of starting plasma Significant upside pote
Slide 9: Strong Balance Sheet & Top Tier Earnings Growth Outlook
Strong Balance Sheet & Top Tier Earnings Growth Outlook Strong Balance Sheet Supports Capital Allocation Optionality Revenue Growth Driving Top-Tier Earnings Outlook Screen and identify high-titer RSV plasma donors Hyperimmune donors with sufficient antibodies to select pathogens are identified Tail
Slide 10: Commercial Opportunities: Plasma Products Portfolio
Commercial Opportunities: PLASMA PRODUCTS PORTFOLIO NASDAQ: ADMA
Slide 11: Plasma Therapeutics: Introduction to Plasma-Derived Therapies and Immunoglobulins
Plasma Therapeutics Introduction to Plasma-Derived Therapies and Immunoglobulins (IG) ADMA’s optimized IG manufacturing process supports the potential to maximize revenue from each liter of plasma while producing life-sustaining and saving therapies Plasma-derived therapeutics are essential,life-sus
Slide 12: IG Market Is Sizeable & Growing
IG Market Is Sizeable & Growing Current $10.5Bn U.S. IG market expected to grow to $20Bn+ by 2030 Aging Population Geriatric population more susceptible to rare diseases treatable by IG products Global population of 65+ expected to nearly double by 2050 Rise of Use of IGs in Medicine Surge in awaren
Slide 13: Despite Decades of IG Use, Improved Therapies Still Needed
In a 40 year study of 473 patients with PI on standard IVIG (3) Potential Higher-Risk Target Populations (1) Despite Decades of IG Use, Improved Therapies Still Needed PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a l
Slide 14: ASCENIV Overview
ASCENIVTM Overview THE PRODUCTION OF ASCENIV ONLY IVIG PRODUCT MANUFACTURED USING PATENTED DONOR SCREENINGAND PLASMA POOLING METHODS (1) IN A 1-YEAR STUDY OF PATIENTS WITH PI, ASCENIV reported zero serious bacterial infections (SBIs)* * SBIs were defined as a rate of <1.0 cases of bacterial pneumoni
Slide 15: BIVIGAM Overview
BIVIGAM® Overview The Reintroduction of BIVIGAM RESULTS FROM ADMA’S STRONG EXECUTION AND REGULATORY EXPERTISE IN A 1-YEAR STUDY OF PATIENTS WITH PI, BIVIGAM met all primary endpoints (1)(2) * Target was 1 SBI / year; 99% CI of 0.136 SBI / patient/year; of 63 adult patients in the enrolled in the stu
Slide 16: Nabi-HB Overview
Nabi-HB® Overview THE THREAT OF HEPATITIS B NABI-HB PROVIDES PROTECTION AGAINST HEPATITIS B INFECTION WITHIN 24 HOURS OF ADMINISTRATION (7) Anti-HBs = anti-hepatitis B surface antibodies; IU = international units; WHO = World Health Organization; HBIG = hepatitis immunoglobulin; HBV = hepatitis B vi
Slide 17: ADMA's Patented Immunotechnology is Used to Manufacture ASCENIV
ADMA’s Patented Immunotechnology is Used to Manufacture ASCENIV™ PATENTS ISSUED 9,107,906 - Composition 9,714,283 - Use 9,815,886 - Methods Expiration 2035 *These patents include the use of IG for treatment and prevention of all viral induced respiratory infections 17
Slide 18: Commercialization/Distribution Strategy for ADMA's Immunoglobulins
Commercialization/Distribution Strategy for ADMA’s Immunoglobulins Identified and engaged with appropriate channel partners that align with our call planand sites-of-service where there is demand across our immunoglobulin portfolio Distribution channel is well-defined Inpatients – hospital based Out
Slide 19: Plasma Product Manufacturing Overview
Plasma Product Manufacturing Overview PRODUCTION OF PLASMA-DERIVED THERAPIES NASDAQ: ADMA
Slide 20: Fractionation Plants Are Scarce with Only a Few FDA Approved Facilities in the U.S.
Fractionation plants are scarce with only a few companies operating FDA approved facilities in the U.S. World-class, cGMP-compliant plasma fractionation facility and laboratories in Boca Raton, FL; acquired in June 2017 Last FDA compliance inspection completed in August 2021 One of few FDA-approved
Slide 21: Production of Plasma-Derived Therapies
Production of Plasma-Derived Therapies Approximately 4-6 months – includes all in-process bulk testing and batch record reviewand release by ADMA and any 3rd parties Cohn-Oncley Cold Ethanol Fractionation Process (Estimated 7-12 Months) End-to-end control of the supply chain and production processes
Slide 22: In-House Fill-Finish Capabilities: SA25 Workcell
Internal fill-finish production capabilities expected to result in: Product Labeling, Packaging and Serialization SA25 Workcell aseptic fill-finish machine received FDA approval In-house fill-finish capabilities with the FDA approval of theSA25 Workcell In-house specialty team to oversee third-party
Slide 23: Plasma Collection Centers
Plasma Collection Centers ADMA BIOCENTERS PLASMA COLLECTION NETWORK NASDAQ: ADMA
Slide 24: ADMA BioCenters Overview
ADMA BioCenters Overview10 FDA-Licensed Centers Supporting Plasma Self-Sufficiency Plasma collection centers are essential to ensure raw material supply to produce IG and other plasma proteins ADMA BioCenters consists of a network of10 FDA-licensed plasma collection centers Growing internal plasma c
Slide 25: Milestones, Corporate and Financial Highlights
Milestones, Corporate and Financial Highlights FINACIAL OVERVIEW NASDAQ: ADMA
Slide 26: Experienced Management Team and Board of Directors
Experienced Management Team and Board of Directors NAME SELECTED CURRENT OR PAST AFFILIATIONS Adam GrossmanFounder, President, CEO & Director, Interim CFO Dr. Jerrold GrossmanFounder & Vice Chairman Lawrence GuiheenDirector Bryant FongDirector Steven ElmsChairman Young Kwon, Ph.D.Director Alison Fin
Slide 27: Financial Overview
Financial Overview Current Financial Overview Three Months Ended March 31, 2024 Three Months Ended March 31, 2023 Revenues $81.9M $56.9M Gross Profit $39.1M $16.5M Adjusted EBITDA(1) $26.4M $2.5M Net Income/(Loss) $17.8M ($6.8M) Cash and cash equivalents $45.3M $69.2M Total assets $350.9M $340.8M To
Slide 28: Upcoming Milestones
Supply Chain &End-to-End Control Execute on supply chain robustness and establish end-to-end control Advance pre-clinical development of newly introduced S. pneumo hyperimmune globulin Expand BioCenters plasma collection facility network to a total of 10 FDA-licensed centers Utilize strong balance s
Slide 29: Thank You
Thank You NASDAQ: ADMA